AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 121 min read$CMND

HRT FINANCIAL LP purchased $330K of CMND

HRT FINANCIAL LP purchased 2,159,052 shares of Clearmind Medicine Inc. (CMND) at $0.15 ($0.33M total) on 2026-06-10.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jun 12, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CMND
Bullish
medium confidence
Mentioned
$CMND
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMNDBullishLow
01

Why it matters

The newest fact is the disclosed purchase size, price ($0.1530/share), and post-transaction holdings for a 10% owner, which can modestly influence sentiment but lacks fundamental new information.

02

Market read

CMND receives a fresh ownership-increase datapoint from a large holder, which may attract short-term attention but is unlikely to drive a durable repricing alone.

03

What to watch

The filing does not disclose intent, valuation rationale, or whether the buy changes future behavior; traders should watch for subsequent Form 4s or company catalysts.

Relevance 5/10Novelty 8/10Timing: SEC Form 4 filed 2026-06-12 (purchase dated 2026-06-10)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Clearmind Medicine Inc. (CMND).

Company-level read

Ticker impact

$CMNDBullishMedium confidence
Context

HRT Financial LP (10% owner) filed an SEC Form 4 open-market purchase of 2,159,052 CMND shares on 2026-06-10.

Expected impact

Near-term impact likely limited; any effect would be sentiment-driven and may fade unless followed by additional disclosures.

Evidence & confidence

Form 4 insider/institutional buying can support sentiment, but the article provides no new company-specific operating/regulatory/financial development beyond the transaction details.

Market effects

Sector

No sector-level read-through; this is a single-issuer ownership transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Open-market buys can be routine (e.g., liquidity/portfolio rebalancing) and may not reflect a new thesis; without a 10b5-1 plan, it still may be non-informational.

Key entities

  • issuer
    Clearmind Medicine Inc.

    Subject of the Form 4 disclosure; ticker CMND.

  • 10% owner
    HRT Financial LP

    Reported open-market purchase of CMND shares; filed the Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CMND insider trading history →

Related articles

SEP 11
$CMNDMedAI 8/10

Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

finanznachrichten.de2 min
SEP 8
$CMNDMed

Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

rttnews.com2 min
SEP 4
$CMNDMed

Clearmind Tumbles on Buying into Charging Robotics

Clearmind Medicine (CMND) agreed to buy a 51% stake in Charging Robotics, a wireless EV charging solutions provider, for $2.5M. The company will also lend Charging Robotics $1.5M at 4% interest. Charging Robotics' tech offers up to 10 kW continuous charging for automated parking and autonomous vehicles.

baystreet.ca1 min
SEP 1
$CMNDMedAI 8/10

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Medicine (CMND) has started Phase IIa of its trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled. The trial is evaluating safety, tolerability, and preliminary efficacy. The company reported positive data from earlier trial phases, supporting continued development. CMND-100 is Clearmind's lead investigational psychedelic-based therapeutic.

sina.com.hk2 min
AUG 13
$CMNDMed

Clearmind Medicine Inc.: Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

Clearmind Medicine (Nasdaq: CMND) said its independent DSMB approved advancing its FDA-regulated Phase I/II trial of CMND-100 for alcohol use disorder from Part A to Parts B and C. Part A met the primary safety endpoint in healthy participants. Part B will test 80 mg and 160 mg in AUD patients; Part C will test 160 mg in healthy participants.

finanznachrichten.de4 min